NEW YORK (GenomeWeb News) – Barcelona-based plasma products manufacturer Grifols has acquired a 60 percent stake in Progenika Biopharma for €37 million ($48.4 million), the firms announced earlier this week.

Grifols paid 50 percent of the consideration in cash, with the other 50 percent coming in the form of non-voting (Class B) Grifols shares.

Vizcaya, Spain-based Progenika develops molecular diagnostics tests and DNA chips for disease diagnosis and prognosis. In particular, it has developed tests for evaluating transfusional compatibility studies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.